Healey Kelley R, Perlin David S
Department of Biology, William Paterson University, Wayne, NJ 07470, USA.
Public Health Research Institute, New Jersey Medical School, Rutgers Biomedical and Health Sciences, Newark, NJ 07103, USA.
J Fungi (Basel). 2018 Sep 1;4(3):105. doi: 10.3390/jof4030105.
has thoroughly adapted to successfully colonize human mucosal membranes and survive in vivo pressures. prior to and during antifungal treatment. Out of all the medically relevant species, has emerged as a leading cause of azole, echinocandin, and multidrug (MDR: azole + echinocandin) adaptive resistance. Neither mechanism of resistance is intrinsic to , since stable genetic resistance depends on mutation of drug target genes, and (echinocandin resistance), and a transcription factor, , which controls expression of major drug transporters, such as (azole resistance). However, another hallmark of is the ability to withstand drug pressure both in vitro and in vivo prior to stable "genetic escape". Additionally, these resistance events can arise within individual patients, which underscores the importance of understanding how this fungus is adapting to its environment and to drug exposure in vivo. Here, we explore the evolution of echinocandin resistance as a multistep model that includes general cell stress, drug adaptation (tolerance), and genetic escape. The extensive genetic diversity reported in is highlighted.
已完全适应成功定殖于人类黏膜并在体内压力下存活。在抗真菌治疗之前及期间。在所有医学相关物种中,已成为唑类、棘白菌素和多药(MDR:唑类 + 棘白菌素)适应性耐药的主要原因。两种耐药机制均非该菌固有,因为稳定的遗传耐药取决于药物靶基因的突变,以及(棘白菌素耐药)和一种转录因子,其控制主要药物转运蛋白的表达,如(唑类耐药)。然而,该菌的另一个特征是在稳定的“遗传逃逸”之前在体外和体内均能耐受药物压力。此外,这些耐药事件可在个体患者体内发生,这凸显了了解这种真菌如何适应其环境以及体内药物暴露情况的重要性。在此,我们将棘白菌素耐药的演变探索为一个多步骤模型,包括一般细胞应激、药物适应(耐受)和遗传逃逸。强调了该菌报道的广泛遗传多样性。